Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Compiled:BIG PHARMA AND POTENTIAL PARTNER DISCUSSION: 09/26/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 317
Posts 40,607
Boards Moderated 29
Alias Born 09/20/01
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
XenaLives Member Level  Thursday, 09/26/19 10:24:57 AM
Re: None
Post # of 232262 
Compiled:BIG PHARMA AND POTENTIAL PARTNER DISCUSSION: 09/26/19
_____________________________________________________________________________________________
Published: 23 August 2019
History and progress of hypotheses and clinical trials for Alzheimer’s disease (from Greenspam3)
https://www.nature.com/articles/s41392-019-0063-8
Comments on above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150735844
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150738103
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150738889
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150739265

Eisai's PR on the Elenbecestat trial failure. (from Talon38)
http://eisai.mediaroom.com/2019-09-13-Eisai-And-Biogen-To-Discontinue-Phase-III-Clinical-Studies-Of-BACE-Inhibitor-Elenbecestat-In-Early-Alzheimers-Disease

The Drug industry's influence over research:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142652537

How the Alzheimer’s Cabal Thwarted Research for 30 years! (from Biostockclub)
https://www.statnews.com/2019/06/25/alzheimers-cabal-thwarted-progress-toward-cure/

Why Big Pharma's plaque attack trials failed:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149743210

Commonly prescribed drugs are tied to nearly 50% higher dementia risk in older adults, study says (from kevli33).
https://www.cnn.com/2019/06/24/health/dementia-risk-drug-study/index.html

Is the Alzheimer's epidemic the result of bad pharma and bad psychiatry?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142358853

Biogen needs something like us. Bad.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150304707

Takeda or Eisai?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149621171

Eisai trying to emulate Anavex approach:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149720753
Eisai PR not behind paywall 6/13/18:
https://www.eisai.com/news/2018/news201847.html

Eisai’s AD pipeline...caving?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150096459

Changes at Eisai:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150051924

The “next wave” of BP’s being incubated now, in the form of small, smart, faster biotechs! 4/23/19 article:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148381829

Merck and 21st Century Medicine
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148109429

Merck and the Canadians team up:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148108335
https://www.eurekalert.org/pub_releases/2017-03/mu-npt031717.php

Roche and Genentech - a case study:

https://knowledge.wharton.upenn.edu/article/anatomy-of-a-merger-hostile-deals-become-friendly-in-the-end-right/

Why modern medicine is like the medieval church:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146539971

Below is a link to a 6-part article that shines a bright light on big pharma's influence in the market, research and fake news... rather revealing! (from basparks79)
https://articles.mercola.com/sites/articles/archive/2017/12/27/drug-safety-media-shaped-by-big-pharma.aspx

Biogen on the Brink
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=150304707&txt2find=biogen

BIIB's problem with their Alzheimer's trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144801572

Bayer also bailing on R&D:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145174145

Why did Big Pharma bail on Alzheimer's trials early 2018? Possible Answer:
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596728.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145205259
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214094
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145215823
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145214295

“Watch: How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?”
By Damian Garde @damiangarde and Alex Hogan @hoganalex
May 21, 2019
(from kevli33)
https://www.statnews.com/2019/05/21/alzheimers-disease-amyloid-hypothesis-history/

(see also MS section)

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist